The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

The US Food and Drug Administration (FDA) has accepted for review Regeneron Pharmaceuticals’ resubmission of the Biologics ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

US biotech Regeneron Pharmaceuticals says that its investigational gene therapy DB-OTO showed clinically-meaningful hearing ...

Regeneron Pharmaceuticals has reported positive ... as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score. Subjects treated with the injection every eight weeks ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

Regeneron Pharmaceuticals is taking another ... the FDA cited the study’s progress as the reason for issuing a complete response letter (CRL), marking the first time the agency had used this ...

This was despite the upcoming patent expirations. It stated the following in its Q3 2024 investor letter: “We purchased Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biopharmaceutical ...